236 related articles for article (PubMed ID: 17429838)
1. High prevalence of p53 exon 4 mutations in soft tissue sarcoma.
Das P; Kotilingam D; Korchin B; Liu J; Yu D; Lazar AJ; Pollock RE; Lev D
Cancer; 2007 Jun; 109(11):2323-33. PubMed ID: 17429838
[TBL] [Abstract][Full Text] [Related]
2. The p53 gene in soft tissue sarcomas: prognostic value of DNA sequencing versus immunohistochemistry.
Taubert H; Würl P; Bache M; Meye A; Berger D; Holzhausen HJ; Hinze R; Schmidt H; Rath FW
Anticancer Res; 1998; 18(1A):183-7. PubMed ID: 9568075
[TBL] [Abstract][Full Text] [Related]
3. p53 gene mutations and p53 protein expression in human soft tissue sarcomas.
Yoo J; Lee HK; Kang CS; Park WS; Lee JY; Shim SI
Arch Pathol Lab Med; 1997 Apr; 121(4):395-9. PubMed ID: 9140310
[TBL] [Abstract][Full Text] [Related]
4. p53 Mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer.
Makino T; Yamasaki M; Miyata H; Yoshioka S; Takiguchi S; Fujiwara Y; Nakajima K; Nishida T; Mori M; Doki Y
Ann Surg Oncol; 2010 Mar; 17(3):804-11. PubMed ID: 19885698
[TBL] [Abstract][Full Text] [Related]
5. Infrequent p53 gene mutations and lack of p53 protein expression in clear cell sarcoma of the kidney: immunohistochemical study and mutation analysis of p53 in renal tumors of unfavorable prognosis.
Hsueh C; Wang H; Gonzalez-Crussi F; Lin JN; Hung IJ; Yang CP; Jiang TH
Mod Pathol; 2002 Jun; 15(6):606-10. PubMed ID: 12065773
[TBL] [Abstract][Full Text] [Related]
6. Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas.
Liu FS; Kohler MF; Marks JR; Bast RC; Boyd J; Berchuck A
Obstet Gynecol; 1994 Jan; 83(1):118-24. PubMed ID: 8272291
[TBL] [Abstract][Full Text] [Related]
7. p53 protein expression does not correlate with EBV status in childhood B non-Hodgkin lymphomas.
Klumb CE; Hassan R; Zalcberg IR; Resende LM; Carriço MK; Maia RC
Pediatr Blood Cancer; 2004 Aug; 43(2):115-9. PubMed ID: 15236276
[TBL] [Abstract][Full Text] [Related]
8. p53 immunoreactivity and single-strand conformational polymorphism analysis often fail to predict p53 mutational status.
Tolbert DM; Noffsinger AE; Miller MA; DeVoe GW; Stemmermann GN; Macdonald JS; Fenoglio-Preiser CM
Mod Pathol; 1999 Jan; 12(1):54-60. PubMed ID: 9950163
[TBL] [Abstract][Full Text] [Related]
9. Sequencing analysis of RNA and DNA of exons 1 through 11 shows p53 gene alterations to be present in almost 100% of head and neck squamous cell cancers.
Kropveld A; Rozemuller EH; Leppers FG; Scheidel KC; de Weger RA; Koole R; Hordijk GJ; Slootweg PJ; Tilanus MG
Lab Invest; 1999 Mar; 79(3):347-53. PubMed ID: 10092071
[TBL] [Abstract][Full Text] [Related]
10. Mutations in p53 are frequent in the preneoplastic stage of mouse mammary tumor development.
Jerry DJ; Ozbun MA; Kittrell FS; Lane DP; Medina D; Butel JS
Cancer Res; 1993 Jul; 53(14):3374-81. PubMed ID: 8324748
[TBL] [Abstract][Full Text] [Related]
11. High frequency of frameshift mutation on p53 gene in Taiwanese with non small cell lung cancer.
Chang MY; Chong IW; Chen FM; Wang JY; Cheng TL; Cheng YJ; Sheu CC; Hung SY; Yang MC; Lin SR
Cancer Lett; 2005 May; 222(2):195-204. PubMed ID: 15863268
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical detection of p53 protein overexpression versus gene sequencing in urinary bladder carcinomas.
Bernardini S; Adessi GL; Billerey C; Chezy E; Carbillet JP; Bittard H
J Urol; 1999 Oct; 162(4):1496-501. PubMed ID: 10492244
[TBL] [Abstract][Full Text] [Related]
13. P53 gene mutation spectrum and the relationship between gene mutation and protein levels in pterygium.
Tsai YY; Cheng YW; Lee H; Tsai FJ; Tseng SH; Chang KC
Mol Vis; 2005 Jan; 11():50-5. PubMed ID: 15682042
[TBL] [Abstract][Full Text] [Related]
14. Immunofluorometric assay of p53 protein versus sequencing of p53 exons 5 to 9 for the detection of p53 abnormalities in ovarian carcinoma.
Lianidou ES; Levesque MA; Katsaros D; Angelopoulou K; Yu H; Genta F; Arisio R; Massobrio M; Bharaj B; Diamandis EP
Anticancer Res; 1999; 19(1B):749-56. PubMed ID: 10216487
[TBL] [Abstract][Full Text] [Related]
15. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
Griewe GL; Dean RC; Zhang W; Young D; Sesterhenn IA; Shanmugam N; McLeod DG; Moul JW; Srivastava S
Prostate Cancer Prostatic Dis; 2003; 6(4):281-5. PubMed ID: 14663467
[TBL] [Abstract][Full Text] [Related]
16. High frequency of p53 gene mutation in adenocarcinomas of the gallbladder.
Fujii K; Yokozaki H; Yasui W; Kuniyasu H; Hirata M; Kajiyama G; Tahara E
Cancer Epidemiol Biomarkers Prev; 1996 Jun; 5(6):461-6. PubMed ID: 8781743
[TBL] [Abstract][Full Text] [Related]
17. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
[TBL] [Abstract][Full Text] [Related]
18. Mutations of p53 in gallbladder carcinomas in high-incidence areas of Japan and Chile.
Yokoyama N; Hitomi J; Watanabe H; Ajioka Y; Pruyas M; Serra I; Shirai Y; Hatakeyama K
Cancer Epidemiol Biomarkers Prev; 1998 Apr; 7(4):297-301. PubMed ID: 9568784
[TBL] [Abstract][Full Text] [Related]
19. Expression and alteration of ras and p53 proteins in patients with lung carcinoma accompanied by idiopathic pulmonary fibrosis.
Takahashi T; Munakata M; Ohtsuka Y; Nisihara H; Nasuhara Y; Kamachi-Satoh A; Dosaka-Akita H; Homma Y; Kawakami Y
Cancer; 2002 Aug; 95(3):624-33. PubMed ID: 12209756
[TBL] [Abstract][Full Text] [Related]
20. Mutation of the p53 gene in postradiation sarcoma.
Nakanishi H; Tomita Y; Myoui A; Yoshikawa H; Sakai K; Kato Y; Ochi T; Aozasa K
Lab Invest; 1998 Jun; 78(6):727-33. PubMed ID: 9645763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
